Europe Liquid Biopsy Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2024 –2030 |
 Marktgröße (Basisjahr) | |
 Marktgröße (Prognosejahr) | |
 CAGR |
% |
| Wichtige Marktteilnehmer |
>Europäischer Markt für Flüssigbiopsie, nach Produkt (Instrumente, Verbrauchsmaterialien und Zubehör, Dienstleistungen und Software), Biomaker-Typ ( zirkulierende Tumorzellen (CTCS) , zirkulierende zellfreie DNA (CFDNA), zellfreie RNA, extrazelluläre Vesikel, Exosomen und andere), Probentyp (auf Blutprobenbasis, Urinprobenbasis, Speichel- und anderen Gewebeflüssigkeitsprobenbasis und andere), Analysetyp (Molekular-, Proteomik- und Histologie-/Bildgebungsanalyse), Anwendungstyp (Krebsanwendungen und Nicht-Krebsanwendungen), klinische Anwendung (Routine-Screening, Patientenuntersuchung, Therapieauswahl, Behandlungsüberwachung, Rezidivüberwachung und andere), Technologie (Parallelanalyse mehrerer Gene und Einzelgenanalyse), Endbenutzer (Krankenhäuser, Referenzlabore, Diagnosezentren, Forschungszentren und akademische Institute und andere), Vertriebskanal (Direktausschreibung, Drittanbieter und andere) – Branchentrends und Prognose bis 2030.
Flüssigbiopsie-Marktanalyse und Einblicke in Europa
Das zunehmende Bewusstsein für fortschrittliche Diagnosetechnologie in Europa hat die Nachfrage nach diesem Markt erhöht. Die steigenden Gesundheitsausgaben für bessere Gesundheitsdienste tragen ebenfalls zum Wachstum des Marktes bei. Die wichtigsten Marktteilnehmer konzentrieren sich in dieser entscheidenden Phase auf die Einführung und Zulassung verschiedener Dienste. Darüber hinaus trägt auch die zunehmende Weiterentwicklung von Prozessen und Techniken zur steigenden Nachfrage nach Flüssigbiopsien bei.
Der europäische Markt für Flüssigbiopsien dürfte im Prognosejahr aufgrund der Zunahme der Marktteilnehmer und der Verfügbarkeit fortschrittlicher Dienste wachsen. Darüber hinaus sind die Hersteller in Entwicklungsaktivitäten involviert, um neue Dienste auf den Markt zu bringen. Die zunehmende Entwicklung im Bereich fortschrittlicher Gesundheitstechniken fördert das Marktwachstum zusätzlich.
Schwierigkeiten wie das Fehlen standardisierter Protokolle und der Mangel an qualifiziertem Fachpersonal könnten jedoch das Wachstum des europäischen Flüssigbiopsiemarktes im Prognosezeitraum behindern.
Data Bridge Market Research analysiert, dass der europäische Markt für Flüssigbiopsien im Prognosezeitraum von 2023 bis 2030 mit einer durchschnittlichen jährlichen Wachstumsrate von 15,1 % wachsen wird.
|
Berichtsmetrik |
Details |
|
Prognosezeitraum |
2023 bis 2030 |
|
Basisjahr |
2022 |
|
Historische Jahre |
2021 (anpassbar auf 2015–2020) |
|
Quantitative Einheiten |
Umsatz in Millionen, Mengen in Einheiten, Preise in USD |
|
Abgedeckte Segmente |
Produkt (Instrumente, Verbrauchsmaterialien und Zubehör, Dienstleistungen und Software), Biomaker-Typ (zirkulierende Tumorzellen (CTCS), zirkulierende zellfreie DNA (CFDNA), zellfreie RNA, extrazelluläre Vesikel, Exosomen und andere), Probentyp (auf Blutprobenbasis, auf Urinprobenbasis, auf Speichel- und anderen Gewebeflüssigkeitsproben basierend und andere), Analysetyp (Molekular-, Proteomik- und Histologie/Bildgebung), Anwendungstyp (Krebsanwendungen und Nicht-Krebsanwendungen), klinische Anwendung (Routine-Screening, Patientenuntersuchung, Therapieauswahl, Behandlungsüberwachung, Rezidivüberwachung und andere), Technologie (Parallelanalyse mehrerer Gene und Einzelgenanalyse), Endbenutzer (Krankenhäuser, Referenzlabore, Diagnosezentren, Forschungszentren und akademische Institute und andere), Vertriebskanal (Direktausschreibung, Drittanbieter und andere) |
|
Abgedeckte Länder |
Deutschland, Großbritannien, Frankreich, Italien, Spanien, Niederlande, Russland, Schweiz, Türkei, Belgien und Rest von Europa |
|
Abgedeckte Marktteilnehmer |
F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, mdxhealth, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., Menarini Silicon Biosystems, Sysmex Inostics Inc. und ANGLE plc unter anderem |
Marktdefinition
Eine Flüssigbiopsie ist ein medizinischer Test, bei dem verschiedene Biomoleküle wie DNA, RNA, Proteine und andere Substanzen im Blut oder anderen Körperflüssigkeiten eines Patienten analysiert werden, um verschiedene Erkrankungen, darunter auch Krebs, zu diagnostizieren und zu überwachen. Im Gegensatz zu herkömmlichen Biopsien, bei denen Gewebeproben aus dem Körper entnommen werden, ist eine Flüssigbiopsie nicht invasiv und kann wichtige diagnostische Informationen liefern, ohne dass eine Operation oder andere invasive Verfahren erforderlich sind. Flüssigbiopsien befinden sich noch in der frühen Entwicklungsphase, versprechen jedoch eine Verbesserung der Erkennung und Behandlung von Krebs und anderen Krankheiten.
Flüssigbiopsie-Marktdynamik in Europa
In diesem Abschnitt geht es um das Verständnis der Markttreiber, Vorteile, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert.
Treiber
- Steigende Nachfrage nach nicht-invasiver Liquid-Biopsy-Technik
Bei Flüssigbiopsien werden tumorabgeleitete Einheiten wie zirkulierende Tumorzellen, zirkulierende Tumor-DNA und Tumor-Extrazellularvesikel, die in den Körperflüssigkeiten von Krebspatienten vorhanden sind, isoliert und anschließend die darin enthaltenen genomischen und proteomischen Daten analysiert. Wie in der Übersicht beschrieben, haben sich die Methoden zur Isolierung und Analyse von Flüssigbiopsien in den letzten Jahren rasant weiterentwickelt und liefern nun mehr Details über Tumormerkmale wie Mutationen, Tumorstadien, Tumorprogression, Heterogenität sowie Gen- und Klonentwicklung. Flüssigbiopsien von Krebspatienten haben neue Möglichkeiten bei der Erkennung und kontinuierlichen Überwachung, der Behandlung auf der Grundlage von Präzisionsmedizin und dem Screening von Markern auf therapeutische Resistenz eröffnet. Nichtinvasive Krebsdiagnostik bietet einen sichereren und patientenfreundlicheren Ansatz, was zu einer wachsenden Nachfrage nach diesen Methoden führt.
- Fortschritte in der Präzisionsmedizin durch Flüssigbiopsie
Eine präzise medizinische Onkologie in der klinischen Behandlung von Krebs kann durch die Diagnoseplattform „Liquid Biopsy“ (LB) erreicht werden. Die LB wurde als leistungsstarker Echtzeitansatz für die molekulare Überwachung dieser dynamischen Krebserkrankung anerkannt. Diese Methode nutzt die Erkennung von Biomarkern im Blut für Prognose- und Vorhersagezwecke mit nicht-invasiven Mitteln, was in naher Zukunft einen Paradigmenwechsel im Verständnis der Molekularbiologie und der Heterogenität von Tumoren darstellen wird. Fortschritte in der Präzisionsmedizin, die durch den Einsatz von Liquid-Biopsy-Techniken vorangetrieben werden, haben erheblich zur wachsenden Nachfrage nach nicht-invasiver Krebsdiagnostik beigetragen. Liquid-Biopsy-Techniken wie die Analyse zirkulierender Tumor-DNA (ctDNA), zirkulierender Tumorzellen (CTCs) oder Exosomen im Blut oder anderen Körperflüssigkeiten liefern wertvolle Informationen über die genetische Zusammensetzung von Tumoren und ermöglichen präzise medizinische Ansätze in der Krebsbehandlung.
Gelegenheit
- Integration von Künstlicher Intelligenz (KI) und maschinellem Lernen
Auf Flüssigbiopsie basierende Ansätze bieten viele neue Möglichkeiten, molekulare Biomarker zur Diagnose, Prognose und Überwachung von Krankheiten zu messen. Künstliche Intelligenz (KI), wie z. B. maschinelles Lernen, und ihre Fähigkeit, Signaturen spezifischer Krankheitszustände in Multiplexdaten zu identifizieren, werden der Schlüssel zur Nutzung der neuen molekularen Informationen sein, die mikrochipbasierte Diagnostik extrahieren kann.
Daher ist zu erwarten, dass die Integration von KI und maschinellem Lernen eine Chance für das Wachstum des Marktes darstellt.
- Steigende Erstattungen und staatliche Unterstützung für die Flüssigbiopsie
Die Einführung der Flüssigbiopsie wurde maßgeblich durch staatliche Unterstützung beeinflusst. Regierungen auf der ganzen Welt haben Gesetze erlassen, um die Einführung der Flüssigbiopsie zu fördern, weil sie wissen, wie sie die Patientenversorgung verbessern, die Gesundheitskosten senken und die Präzisionsmedizin voranbringen kann. Die Einbeziehung der Flüssigbiopsie in nationale Krebsvorsorgeprogramme oder Behandlungsempfehlungen ist nur ein Beispiel dafür, wie dies erreicht werden könnte. Weitere Beispiele sind die Finanzierung der Forschung und Entwicklung von Flüssigbiopsietechnologien und die Unterstützung klinischer Studien und Untersuchungen zum Nachweis ihrer therapeutischen Wirksamkeit. Diese staatliche Unterstützung hat dazu beigetragen, das Wissen über Flüssigbiopsietests, ihre Einführung und ihre Kostenerstattung zu verbessern.
Daher ist zu erwarten, dass die steigenden Erstattungen und die staatliche Unterstützung der Flüssigbiopsie eine Chance für das Marktwachstum darstellen.
Einschränkung/Herausforderung
- Hohe Kosten für Liquid-Biopsy-Tests
Die hohen Kosten der Flüssigbiopsie sind ein großes Hindernis. Flüssigbiopsietests sind zwar vielversprechend für die nichtinvasive Erkennung und Überwachung von Krankheiten, darunter auch Krebs, doch es gibt kostenbedingte Hindernisse, die ihre weitverbreitete Nutzung verhindern könnten.
Die Notwendigkeit spezieller Werkzeuge und Technologien ist eines der größten wirtschaftlichen Hindernisse. Für Flüssigbiopsiestudien werden häufig teure Werkzeuge benötigt, darunter digitale PCR-Geräte, NGS-Plattformen und automatisierte Probenverarbeitungssysteme. Kleinere Gesundheitseinrichtungen mit knapperen Budgets haben möglicherweise Schwierigkeiten, die anfänglichen Investitionen und laufenden Wartungskosten dieser Technologien zu tragen, was ihre Kapazitäten zur Durchführung von Flüssigbiopsieuntersuchungen für Patienten einschränkt.
Daher ist zu erwarten, dass die hohen Kosten von Liquid-Biopsy-Tests das Marktwachstum bremsen werden.
- Mangel an qualifiziertem Fachpersonal für die Durchführung von Flüssigbiopsien
Die Nachfrage nach Liquid-Biopsy-Tests steigt aufgrund ihres potenziellen klinischen Nutzens bei der Krebserkennung, -überwachung und personalisierten Behandlungsentscheidung. Allerdings stehen möglicherweise nur begrenzte Ressourcen wie Personal, Ausrüstung und Finanzierung zur Unterstützung der Umsetzung von Liquid-Biopsy-Programmen in Gesundheitseinrichtungen zur Verfügung. Dies kann zu einem Mangel an qualifiziertem Personal führen, das Liquid-Biopsy-Tests durchführen kann, insbesondere in Regionen oder Gesundheitseinrichtungen mit begrenzten Ressourcen.
Daher ist zu erwarten, dass der Mangel an qualifiziertem Personal für die Durchführung von Flüssigbiopsien das Marktwachstum bremsen wird.
Jüngste Entwicklung
- Im Januar 2022 gab Exact Sciences Corporation die Übernahme von Prevention Genetics, einem genetischen Testlabor, bekannt, um sein Portfolio im Bereich der fortschrittlichen Krebsdiagnostik zu ergänzen und seinen Einstieg in die Erbkrebsdiagnostik (HCT) zu unterstützen.
Europa Flüssigbiopsie Marktumfang
Der europäische Markt für Flüssigbiopsien ist in neun wichtige Segmente unterteilt: Produkt, Biomaker-Typ, Probentyp, Analysetyp, Anwendungstyp, klinische Anwendung, Technologie, Endbenutzer und Vertriebskanal. Das Wachstum dieser Segmente hilft Ihnen bei der Analyse der Marktwachstumssegmente in den Branchen und bietet den Benutzern einen wertvollen Marktüberblick und Markteinblicke, die ihnen bei der strategischen Entscheidungsfindung zur Identifizierung der wichtigsten Marktanwendungen helfen.
Produkt
- Instrumente
- Verbrauchsmaterial und Zubehör
- Dienstleistungen & Software
Auf Produktbasis ist der Markt in Instrumente, Verbrauchsmaterialien und Zubehör, Dienstleistungen und Software segmentiert.
Biomaker-Typ
- Zirkulierende Tumorzellen (CTCS)
- Zirkulierende zellfreie DNA (CFDNA)
- Zellfreie RNA
- Exosomen
- Extrazelluläre Vesikel
- Sonstiges
Auf der Grundlage des Biomaker-Typs ist der Markt in zirkulierende Tumorzellen (CTCS), zirkulierende zellfreie DNA (CFDNA), zellfreie RNA, extrazelluläre Vesikel, Exosomen und andere segmentiert.
Probentyp
- Blutprobenbasiert
- Auf Urinproben basierend
- Speichel und andere Gewebeflüssigkeiten auf Probenbasis
- Sonstiges
Auf der Grundlage des Probentyps wird der Markt in folgende Segmente unterteilt: Blutproben, Urinproben, Speichel- und andere Gewebeflüssigkeitsproben usw.
Analytischer Typ
- Molekular
- Proteomik
- Histologie/Bildgebung
Auf der Grundlage des Analysetyps ist der Markt in die Bereiche Molekularanalyse, Proteomik und Histologie/Bildgebung segmentiert.
Anwendung
- Anwendungen bei Krebserkrankungen
- Nicht-Krebs-Anwendungen
Auf der Grundlage des Anwendungstyps wird der Markt in Krebsanwendungen und Nichtkrebsanwendungen segmentiert.
Klinische Anwendung
- Routine-Screening
- Therapieauswahl
- Behandlungsüberwachung
- Wiederholungsüberwachung
- Patientenuntersuchung
- Sonstiges
Auf der Grundlage der klinischen Anwendung wird der Markt in Routinescreening, Patientenuntersuchung, Therapieauswahl, Behandlungsüberwachung, Rezidivüberwachung und Sonstiges segmentiert.
Technologie
- Multi-Gen-Parallelanalyse
- Einzelgenanalyse
Auf der Grundlage der Technologie ist der Markt in parallele Multigenanalysen und Einzelgenanalysen segmentiert.
Endbenutzer
- Krankenhäuser
- Referenzlabore
- Diagnostikzentren
- Forschungszentren und akademische Institute
- Sonstiges
Auf der Grundlage des Endbenutzers ist der Markt in Krankenhäuser, Referenzlabore, Diagnosezentren, Forschungszentren und akademische Institute usw. segmentiert.
Vertriebskanäle
- Direkte Ausschreibung
- Drittanbieter-Distributor
- Sonstiges
Auf der Grundlage des Vertriebskanals wird der Markt in Direktausschreibungen, Drittanbieter und Sonstige segmentiert.
Europa Flüssigbiopsie Markt – Regionale Analyse/Einblicke
Der europäische Markt für Flüssigbiopsien wird analysiert und es werden Erkenntnisse und Trends zur Marktgröße basierend auf Produkt, Biomaker-Typ, Probentyp, Analysetyp, Anwendungstyp, klinischer Anwendung, Technologie, Endbenutzer und Vertriebskanal bereitgestellt.
Die in diesem Marktbericht abgedeckten Länder sind Deutschland, Großbritannien, Frankreich, Italien, Spanien, Niederlande, Russland, Schweiz, Türkei, Belgien und der Rest von Europa.
Im Jahr 2023 wird Deutschland aufgrund der zunehmenden Verbreitung und Sensibilisierung für Krebs voraussichtlich die Region Europa dominieren; die Nachfrage in dieser Region dürfte durch die Zunahme der Krebsfälle getrieben werden.
Der Länderabschnitt des Berichts enthält auch einzelne marktbeeinflussende Faktoren und Änderungen der Marktregulierung, die sich auf die aktuellen und zukünftigen Trends des Marktes auswirken. Datenpunkte wie die Analyse der nachgelagerten und vorgelagerten Wertschöpfungskette, technische Trends, Porters Fünf-Kräfte-Analyse und Fallstudien sind einige der Hinweise, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Bereitstellung einer Prognoseanalyse der Länderdaten werden auch die Präsenz und Verfügbarkeit europäischer Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen inländischer Zölle und Handelsrouten berücksichtigt.
Wettbewerbsumfeld und Marktanteilsanalyse für Flüssigbiopsie in Europa
Die Wettbewerbslandschaft des europäischen Flüssigbiopsiemarkts bietet Details nach Wettbewerbern. Zu den Details gehören Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Präsenz in Europa, Produktionsstandorte und -anlagen, Stärken und Schwächen des Unternehmens, Produkteinführung, klinische Studienpipelines, Markenanalyse, Produktzulassungen, Patente, Produktbreite und -umfang, Anwendungsdominanz, Technologie-Lebenslinienkurve. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus der Unternehmen in Bezug auf den europäischen Flüssigbiopsiemarkt.
Zu den wichtigsten Akteuren auf dem europäischen Markt für Flüssigbiopsien zählen unter anderem F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, mdxhealth, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., Menarini Silicon Biosystems, Sysmex Inostics Inc. und ANGLE plc.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE LIQUID BIOPSY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET TESTING TYPE COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 INDUSTRY INSIGHTS:
6 EUROPE LIQUID BIOPSY MARKET, REGULATION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE
7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY
7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS
7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS
7.2 RESTRAINTS
7.2.1 HIGH COST OF LIQUID BIOPSY TESTS
7.2.2 LACK OF STANDARDIZED GUIDELINES
7.3 OPPORTUNITIES
7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING
7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY
7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY
7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES
8 EUROPE LIQUID BIOPSY MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 CONSUMABLES & ACCESSORIES
8.2.1 TEST KITS
8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT
8.2.1.2 DNA ISOLATION KIT
8.2.1.3 OTHERS
8.2.2 COLLECTION TUBES
8.2.2.1 50 PIECES
8.2.2.2 100 PIECES
8.2.3 ASSAYS
8.2.3.1 FLEXIBLE REAGENTS
8.2.3.2 SCALABLE REAGENTS
8.2.3.3 OTHERS
8.2.4 CONTROL KIT
8.2.5 OTHERS
8.3 INSTRUMENTS
8.3.1 ANALYZERS
8.3.2 SYSTEMS
8.3.3 OTHERS
8.4 SERVICES & SOFTWARE
8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE
8.4.2 DPCR ANALYSIS SOFTWARE
8.4.3 CASTPCR ANALYSIS SOFTWARE
8.4.4 OTHERS
9 EUROPE LIQUID BIOPSY MARKET, BY BIOMAKER TYPE
9.1 OVERVIEW
9.2 CIRCULATING TUMOR CELLS (CTCS)
9.3 CIRCULATING CELL-FREE DNA (CFDNA)
9.4 CELL-FREE RNA
9.5 EXOSOMES
9.6 EXTRACELLULAR VESICLES
9.7 OTHERS
10 EUROPE LIQUID BIOPSY MARKET, BY SAMPLE TYPE
10.1 OVERVIEW
10.2 BLOOD SAMPLE-BASED
10.3 URINE SAMPLE-BASED
10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED
10.5 OTHERS
11 EUROPE LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE
11.1 OVERVIEW
11.2 MOLECULAR
11.2.1 NGS
11.2.2 PCR
11.2.3 MICROARRAY
11.2.4 PROTEOMICS
11.2.5 OTHERS
11.3 PROTEOMIC
11.3.1 NGS
11.3.2 PCR
11.3.3 MICROARRAY
11.3.4 PROTEOMICS
11.3.5 OTHERS
11.4 HISTOLOGY/IMAGING
12 EUROPE LIQUID BIOPSY MARKET, BY APPLICATION TYPE
12.1 OVERVIEW
12.2 CANCER APPLICATIONS
12.2.1 LUNG
12.2.2 BREAST
12.2.2.1 EARLY BREAST CANCER
12.2.2.2 ADVANCED BREAST CANCER
12.2.3 COLORECTAL
12.2.4 PROSTRATE
12.2.5 LIVER
12.2.6 OTHERS
12.3 NON-CANCER APPLICATIONS
12.3.1 PRENATAL DIAGNOSIS
12.3.2 PERSONALIZED IMMUNOTHERAPY
12.3.3 OTHERS
13 EUROPE LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION
13.1 OVERVIEW
13.2 ROUTINE SCREENING
13.3 THERAPY SELECTION
13.4 TREATMENT MONITORING
13.4.1 EARLY-STAGE DISEASE
13.4.2 LATE-STAGE/METASTATIC DISEASE
13.5 RECURRENCE MONITORING
13.6 PATIENT WORK-UP
13.7 OTHERS
14 EUROPE LIQUID BIOPSY MARKET, BY TECHNOLOGY
14.1 OVERVIEW
14.2 MULTI-GENE-PARALLEL ANALYSIS
14.3 SINGLE GENE ANALYSIS
15 EUROPE LIQUID BIOPSY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 REFERENCE LABORATORIES
15.4 DIAGNOSTIC CENTERS
15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES
15.6 OTHERS
16 EUROPE LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 THIRD PARTY DISTRIBUTOR
16.4 OTHERS
17 EUROPE LIQUID BIOPSY MARKET, BY REGION
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 U.K.
17.1.4 ITALY
17.1.5 SPAIN
17.1.6 RUSSIA
17.1.7 TURKEY
17.1.8 BELGIUM
17.1.9 NETHERLANDS
17.1.10 SWITZERLAND
17.1.11 REST OF EUROPE
18 EUROPE LIQUID BIOPSY MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 COMPANY PROFILE
19.1 F. HOFFMANN-LA ROCHE LTD.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 GUARDANT HEALTH
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 THERMO FISHER SCIENTIFIC INC.
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 SWOT ANALYSIS
19.3.5 PRODUCT PORTFOLIO
19.3.6 RECENT DEVELOPMENTS
19.4 EXACT SCIENCE CORPORATION
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 QIAGEN
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENTS
19.6 ANGLE PLC (2022)
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 BIOCEPT, INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENT
19.8 BIO-RAD LABORATORIES, INC. (2022)
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 EPIC SCIENCES
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 FLUXION BIOSCIENCES INC
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 ILLUMINA, INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 SWOT ANALYSIS
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPMENT
19.12 JOHNSON & JOHNSON PRIVATE LIMITED
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 SWOT ANALYSIS
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPMENTS
19.13 LABORATORY CORPORATION OF AMERICA HOLDINGS
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 SWOT ANALYSIS
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPMENT
19.14 MDXHEALTH
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MENARINI SILICON BIOSYSTEMS
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 NATERA, INC.
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 NEOGENOMICS LABORATORIES
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 ONCOCYTE CORPORATION
19.18.1 COMPANY PROFILE
19.18.2 SERVICE PORTFOLIO
19.18.3 RECENT DEVELOPMENTS
19.19 PATHAI
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 PREDICINE
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENT
19.21 STRECK
19.21.1 COMPANY SNAPSHOT
19.21.2 PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENTS
19.22 SYSMEX INOSTICS INC.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 WAYS IN WHICH LIQUID BIOPSY HAS ADVANCED PRECISION MEDICINE
TABLE 2 EUROPE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 3 EUROPE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 5 EUROPE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 6 EUROPE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 7 EUROPE ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 8 EUROPE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 EUROPE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 10 EUROPE SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 EUROPE SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 12 EUROPE LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 13 EUROPE CIRCULATING TUMOR CELLS (CTCS) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE CIRCULATING CELL-FREE DNA (CFDNA) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE CELL-FREE RNA IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE EXOSOMES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE EXTRACELLULAR VESICLES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 20 EUROPE BLOOD SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE URINE SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 EUROPE SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 EUROPE OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 EUROPE LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 25 EUROPE MOLECULAR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 27 EUROPE PROTEOMIC IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 29 EUROPE HISTOLOGY/IMAGING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 31 EUROPE CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 33 EUROPE BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 34 EUROPE NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 36 EUROPE LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE ROUTINE SCREENING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE THERAPY SELECTION IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 41 EUROPE RECURRENCE MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE PATIENT WORK-UP IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 45 EUROPE MULTI-GENE-PARALLEL ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE SINGLE GENE ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 EUROPE LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 48 EUROPE HOSPITALS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 EUROPE REFERENCE LABORATORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 EUROPE DIAGNOSTICS CENTERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 EUROPE RESEARCH CENTRES AND ACADEMIC INSTITUTES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 EUROPE OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 EUROPE LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 54 EUROPE DIRECT TENDER IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 EUROPE THIRD PARTY DISTRIBUTOR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 EUROPE OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 58 EUROPE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 59 EUROPE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 60 EUROPE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 61 EUROPE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 62 EUROPE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 63 EUROPE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 64 EUROPE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 65 EUROPE ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 66 EUROPE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 67 EUROPE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 68 EUROPE SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 69 EUROPE LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 70 EUROPE LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 71 EUROPE LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 72 EUROPE MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 73 EUROPE PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 74 EUROPE LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 75 EUROPE CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 76 EUROPE BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 77 EUROPE NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 78 EUROPE LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 EUROPE TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 EUROPE LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 81 EUROPE LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 EUROPE LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 83 GERMANY LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 84 GERMANY CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 GERMANY CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 86 GERMANY LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 87 GERMANY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 GERMANY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 89 GERMANY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 90 GERMANY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 91 GERMANY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 92 GERMANY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 93 GERMANY ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 GERMANY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 95 GERMANY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 96 GERMANY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 97 GERMANY SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 98 GERMANY LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 99 GERMANY LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 100 GERMANY LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 101 GERMANY MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 102 GERMANY PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 103 GERMANY LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 104 GERMANY CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 105 GERMANY BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 106 GERMANY NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 107 GERMANY LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 GERMANY TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 GERMANY LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 110 GERMANY LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 111 GERMANY LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 112 FRANCE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 113 FRANCE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 FRANCE CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 115 FRANCE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 116 FRANCE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 117 FRANCE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 118 FRANCE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 119 FRANCE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 120 FRANCE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 121 FRANCE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 122 FRANCE ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 123 FRANCE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 124 FRANCE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 125 FRANCE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 126 FRANCE SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 127 FRANCE LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 128 FRANCE LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 129 FRANCE LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 130 FRANCE MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 131 FRANCE PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 132 FRANCE LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 133 FRANCE CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 134 FRANCE BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 135 FRANCE NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 136 FRANCE LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 137 FRANCE TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 FRANCE LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 139 FRANCE LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 140 FRANCE LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 141 U.K. LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 142 U.K. CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 U.K. CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 144 U.K. LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 145 U.K. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 146 U.K. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 147 U.K. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 148 U.K. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 149 U.K. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 150 U.K. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 151 U.K. ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 152 U.K. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 153 U.K. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 154 U.K. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 155 U.K. SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 156 U.K. LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 157 U.K. LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 158 U.K. LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 159 U.K. MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 160 U.K. PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 161 U.K. LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 162 U.K. CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 163 U.K. BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 164 U.K. NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 165 U.K. LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 166 U.K. TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 167 U.K. LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 168 U.K. LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 169 U.K. LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 170 ITALY LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 171 ITALY CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 172 ITALY CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 173 ITALY LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 174 ITALY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 175 ITALY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 176 ITALY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 177 ITALY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 178 ITALY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 179 ITALY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 180 ITALY ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 ITALY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 182 ITALY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 183 ITALY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 184 ITALY SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 185 ITALY LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 186 ITALY LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 187 ITALY LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 188 ITALY PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 189 ITALY LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 190 ITALY CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 191 ITALY BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 192 ITALY NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 193 ITALY LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 194 ITALY TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 195 ITALY LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 196 ITALY LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 197 ITALY LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 198 SPAIN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 199 SPAIN CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 200 SPAIN CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 201 SPAIN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 202 SPAIN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 203 SPAIN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 204 SPAIN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 205 SPAIN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 206 SPAIN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 207 SPAIN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 208 SPAIN ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 209 SPAIN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 210 SPAIN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 211 SPAIN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 212 SPAIN SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 213 SPAIN LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 214 SPAIN LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 215 SPAIN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 216 SPAIN MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 217 SPAIN PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 218 SPAIN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 219 SPAIN CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 220 SPAIN BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 221 SPAIN NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 222 SPAIN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 223 SPAIN TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 224 SPAIN LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 225 SPAIN LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 226 SPAIN LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 227 RUSSIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 228 RUSSIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 229 RUSSIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 230 RUSSIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 231 RUSSIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 232 RUSSIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 233 RUSSIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 234 RUSSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 235 RUSSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 236 RUSSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 237 RUSSIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 238 RUSSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 RUSSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 240 RUSSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 241 RUSSIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 242 RUSSIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 243 RUSSIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 244 RUSSIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 245 RUSSIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 246 RUSSIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 247 RUSSIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 248 RUSSIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 249 RUSSIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 250 RUSSIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 251 RUSSIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 252 RUSSIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 253 RUSSIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 254 RUSSIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 255 RUSSIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 256 TURKEY LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 257 TURKEY CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 258 TURKEY CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 259 TURKEY LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 260 TURKEY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 261 TURKEY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 262 TURKEY TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 263 TURKEY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 264 TURKEY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 265 TURKEY COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 266 TURKEY ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 267 TURKEY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 268 TURKEY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 269 TURKEY INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 270 TURKEY SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 271 TURKEY LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 272 TURKEY LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 273 TURKEY LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 274 TURKEY MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 275 TURKEY PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 276 TURKEY LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 277 TURKEY CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 278 TURKEY BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 279 TURKEY NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 280 TURKEY LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 281 TURKEY TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 282 TURKEY LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 283 TURKEY LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 284 TURKEY LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 285 BELGIUM LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 286 BELGIUM CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 287 BELGIUM CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 288 BELGIUM LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 289 BELGIUM TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 290 BELGIUM TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 291 BELGIUM TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 292 BELGIUM COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 293 BELGIUM COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 294 BELGIUM COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 295 BELGIUM ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 296 BELGIUM INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 297 BELGIUM INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 298 BELGIUM INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 299 BELGIUM SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 300 BELGIUM LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 301 BELGIUM LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 302 BELGIUM LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 303 BELGIUM MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 304 BELGIUM PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 305 BELGIUM LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 306 BELGIUM CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 307 BELGIUM BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 308 BELGIUM NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 309 BELGIUM LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 310 BELGIUM TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 311 BELGIUM LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 312 BELGIUM LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 313 BELGIUM LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 314 NETHERLANDS LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 315 NETHERLANDS CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 316 NETHERLANDS CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 317 NETHERLANDS LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 318 NETHERLANDS TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 319 NETHERLANDS TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 320 NETHERLANDS TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 321 NETHERLANDS COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 322 NETHERLANDS COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 323 NETHERLANDS COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 324 NETHERLANDS ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 325 NETHERLANDS INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 326 NETHERLANDS INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 327 NETHERLANDS INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 328 NETHERLANDS SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 329 NETHERLANDS LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 330 NETHERLANDS LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 331 NETHERLANDS LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 332 NETHERLANDS MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 333 NETHERLANDS PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 334 NETHERLANDS LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 335 NETHERLANDS CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 336 NETHERLANDS BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 337 NETHERLANDS NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 338 NETHERLANDS LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 339 NETHERLANDS TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 340 NETHERLANDS LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 341 NETHERLANDS LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 342 NETHERLANDS LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 343 SWITZERLAND LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 344 SWITZERLAND CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 345 SWITZERLAND CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 346 SWITZERLAND LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 347 SWITZERLAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 348 SWITZERLAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 349 SWITZERLAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 350 SWITZERLAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 351 SWITZERLAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 352 SWITZERLAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)
TABLE 353 SWITZERLAND ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 354 SWITZERLAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 355 SWITZERLAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 356 SWITZERLAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)
TABLE 357 SWITZERLAND SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 358 SWITZERLAND LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)
TABLE 359 SWITZERLAND LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 360 SWITZERLAND LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 361 SWITZERLAND MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 362 SWITZERLAND PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)
TABLE 363 SWITZERLAND LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 364 SWITZERLAND CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 365 SWITZERLAND BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 366 SWITZERLAND NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)
TABLE 367 SWITZERLAND LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 368 SWITZERLAND TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)
TABLE 369 SWITZERLAND LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 370 SWITZERLAND LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 371 SWITZERLAND LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 372 REST OF EUROPE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
Abbildungsverzeichnis
FIGURE 1 EUROPE LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 2 EUROPE LIQUID BIOPSY MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE LIQUID BIOPSY MARKET: DROC ANALYSIS
FIGURE 4 EUROPE LIQUID BIOPSY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE LIQUID BIOPSY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE LIQUID BIOPSY MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 EUROPE LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 11 THE GROWING DEMAND FOR NON-INVASIVE CANCER DIAGNOSTICS IS EXPECTED TO DRIVE THE EUROPE LIQUID BIOPSY MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 CONSUMABLES & ACCESSORIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LIQUID BIOPSY MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE LIQUID BIOPSY MARKET
FIGURE 14 ADVANTAGES OF LIQUID BIOPSY OVER TRADITIONAL BIOPSY
FIGURE 15 EUROPE LIQUID BIOPSY MARKET: BY PRODUCT, 2022
FIGURE 16 EUROPE LIQUID BIOPSY MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 17 EUROPE LIQUID BIOPSY MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 18 EUROPE LIQUID BIOPSY MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 19 EUROPE LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2022
FIGURE 20 EUROPE LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2023-2030 (USD MILLION)
FIGURE 21 EUROPE LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, CAGR (2023-2030)
FIGURE 22 EUROPE LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, LIFELINE CURVE
FIGURE 23 EUROPE LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2022
FIGURE 24 EUROPE LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)
FIGURE 25 EUROPE LIQUID BIOPSY MARKET: BY SAMPLE TYPE, CAGR (2023-2030)
FIGURE 26 EUROPE LIQUID BIOPSY MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 27 EUROPE LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2022
FIGURE 28 EUROPE LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2023-2030 (USD MILLION)
FIGURE 29 EUROPE LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, CAGR (2023-2030)
FIGURE 30 EUROPE LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, LIFELINE CURVE
FIGURE 31 EUROPE LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2022
FIGURE 32 EUROPE LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2023-2030 (USD MILLION)
FIGURE 33 EUROPE LIQUID BIOPSY MARKET: BY APPLICATION TYPE, CAGR (2023-2030)
FIGURE 34 EUROPE LIQUID BIOPSY MARKET: BY APPLICATION TYPE, LIFELINE CURVE
FIGURE 35 EUROPE LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2022
FIGURE 36 EUROPE LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
FIGURE 37 EUROPE LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, CAGR (2023-2030)
FIGURE 38 EUROPE LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, LIFELINE CURVE
FIGURE 39 EUROPE LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2022
FIGURE 40 EUROPE LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 41 EUROPE LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 42 EUROPE LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 43 EUROPE LIQUID BIOPSY MARKET: BY END USER, 2022
FIGURE 44 EUROPE LIQUID BIOPSY MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 45 EUROPE LIQUID BIOPSY MARKET: BY END USER, CAGR (2023-2030)
FIGURE 46 EUROPE LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 EUROPE LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 48 EUROPE LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 49 EUROPE LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 50 EUROPE LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 EUROPE LIQUID BIOPSY MARKET: SNAPSHOT (2022)
FIGURE 52 EUROPE LIQUID BIOPSY MARKET: BY COUNTRY (2022)
FIGURE 53 EUROPE LIQUID BIOPSY MARKET: BY COUNTRY (2023 & 2030)
FIGURE 54 EUROPE LIQUID BIOPSY MARKET: BY COUNTRY (2022 & 2030)
FIGURE 55 EUROPE LIQUID BIOPSY MARKET: BY PRODUCT (2023-2030)
FIGURE 56 EUROPE LIQUID BIOPSY MARKET: COMPANY SHARE 2022 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
